Literature DB >> 6218567

Activity, stability, and pharmacology of the epimers of moxalactam.

R Wise, N Wright, P J Wills.   

Abstract

By an agar-dilution procedure, the minimal inhibitory concentrations of R, S, and R + S epimers of moxalactam were determined for 23 commonly isolated organisms. Generally the R epimer was twice as active as the S epimer; however, against Pseudomonas aeruginosa the two were equally active. The stability of the epimers and of the R + S mixture in saline and serum was studied by high-pressure liquid chromatography. Each epimer was stable at -20 C. The interconversion half-life in serum at 37 C, 22 C, and 4 C was 1.5, 4.8, and 13 hr, respectively, for R and 1.5, 11, and 43 hr for S. In buffer both epimers were more stable. In buffered saline the final mixture of R:S was 50:50, if one started with either the R or the S epimer. In serum, however, the R:S ratio of the mixture at equilibrium was 45:55. In patients with normal renal function the ratio of R:S in serum at 2 hr was 0.69 and at 8 hr, 0.55. In patients with severe renal failure the R:S ratio at 2 hr was approximately 0.9 and at 6 hr, 0.85. Probably, in renal failure, time is sufficient for re-equilibration of the epimeric mixture, and hence there is little alteration in the R:S ratio with time.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6218567     DOI: 10.1093/clinids/4.supplement_3.s564

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  4 in total

1.  Epimerization kinetics of moxalactam in frozen solution.

Authors:  N Hashimoto; T Ichihashi; E Yamamoto; K Hirano; M Inoue; H Tanaka; H Yamada
Journal:  Pharm Res       Date:  1988-05       Impact factor: 4.200

2.  Epimerization kinetics of moxalactam in frozen urine and plasma samples.

Authors:  N Hashimoto; T Ichihashi; K Hirano; H Yamada
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

3.  High performance liquid chromatographic determination of moxalactam in human plasma and cerebrospinal fluid.

Authors:  J Nielsen; G Karlaganis; H M von Hattingberg; U B Schaad
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 4.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.